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ReviewApelin and its G protein-coupled receptor (GPCR) have
emerged as a key signalling pathway in the cardiovascular
system. The peptide is a potent inotropic agent and
vasodilator. Remarkably, a peptide, Elabela/Toddler, that
has little sequence similarity to apelin, has been proposed
as a second endogenous apelin receptor ligand and is
encoded by a gene from a region of the genome previous-
ly classified as ‘non-coding’. Apelin is downregulated in
pulmonary arterial hypertension and heart failure. To
replace the missing endogenous peptide, ‘biased’ apelin
agonists have been designed that preferentially activate
G protein pathways, resulting in reduced b-arrestin re-
cruitment and receptor internalisation, with the addition-
al benefit of attenuating detrimental b-arrestin signalling.
Proof-of-concept studies support the clinical potential for
apelin receptor biased agonists.
Introduction
Since its discovery in 1993, there is increasing evidence of
the importance of the apelin receptor in the mammalian
cardiovascular system. This review provides an update of
apelin receptor pharmacology, cardiovascular physiology
and pathophysiology, and discusses the role of a second
receptor ligand, Elabela/Toddler. Finally, there is increas-
ing impetus to develop biased apelin receptor agonists for
clinical use.
Apelin receptor discovery, signalling, and distribution
The apelin receptor (also known as APJ, APLNR,
AGTRL1) is a class A GPCR discovered in 1993 based
on its sequence similarity with the angiotensin AT1 recep-
tor [1]. The apelin receptor did not bind angiotensin II and
therefore remained an orphan receptor until the identifi-
cation of apelin as an endogenous ligand in 1998 [2]. The
human (Homo sapiens) apelin receptor consists of 380 ami-
no acids and is identified and conserved in many species,
including mouse (Mus musculus), rat (Rattus norvegicus),
Western clawed frog (Xenopus tropicalis), and zebrafish
(Danio rerio). To date only one apelin receptor has been0165-6147/
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present in amphibians and fish [3,4], and there are no
closely related genes [1].
Apelin responses are in part sensitive to pertussis
toxin, consistent with coupling via Gai [5,6] with addition-
al evidence for involvement of Gaq-linked activation of
phospholipase C (PLC) and protein kinase C (PKC)
[7]. In cardiac development a role for Ga13-activated myo-
cyte enhancer factor 2 has been proposed [8]. Interestingly,
in the heart the apelin receptor may act as a mechan-
osensor for stretch in an apelin-independent/G protein-
independent manner through recruitment of b-arrestin
[9], a protein that initiates receptor internalisation as well
as downstream signalling [10]. Indeed, particular resi-
dues within the receptor have been identified as being
crucial for G protein-independent signalling. Phe 255 and
Trp 259 of the rat apelin receptor (corresponding to Phe
257 and Trp 263 of the human receptor) have been
reported to be absolutely required for rapid receptor inter-
nalisation initiated by the binding of apelin-17 or [Pyr1]-
apelin-13 via an interaction with the C-terminal
phenylalanine residue in the peptide ligands [11]. In
the C terminus, Ser 348, common across species, is essen-
tial for phosphorylation of the receptor following peptide
binding, b-arrestin recruitment, and subsequent receptor
internalisation [12]. Convincing evidence for apelin recep-
tor heterodimerisation in vivo has not yet been obtained in
native tissue; however, in vitro studies suggest that such
receptor complexes may confer novel modes of receptor
activation and signalling [13,14].
There is widespread distribution of apelin receptor in
peripheral organs including heart, lung, kidney, and pla-
centa [3,6,15–17]. Autoradiographical and immunohisto-
chemical detection of receptor protein localised it to
vascular endothelial and smooth muscle cells in addition
to cardiomyocytes [18]. Apelin receptor is also present in
the central nervous system [16,17] but, because peptides
such as apelin are unlikely to cross the blood–brain barrier,
the peripheral and central receptors may be considered as
separate transmitter systems.
Apelin receptor ligands
Endogenous apelin receptor peptides
Evidence indicates that apelin acts as a paracrine/auto-
crine mediator because peptide expression patterns follow
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cardiovascular system, the peptide can be detected in
cardiac and vascular endothelial cells [19]. The structure
of apelin pre-proproteins was deduced following identifica-
tion of an endogenous 36 amino acid peptide (Figure 1) in
bovine stomach extracts [2]. Potential proteolytic cleavage
sites predicted that shorter C-terminal apelin peptides,
apelin-17, apelin-13 and [Pyr1]apelin-13 (Figure 1), may be
biologically relevant; these have been synthesised and
exhibit varying affinities and potencies for the apelin
receptor [4]. However, in human heart [20] and plasma
[21], [Pyr1]apelin-13 was the predominant isoform
detected. Endogenous apelin peptides are derived from
the C terminus of the 77 amino acid precursor pre-proa-
pelin, and sequence alignment from human, rat, and
mouse indicates that the C-terminal 23 amino acids are
fully conserved [4]. Although the synthetic pathways of
biologically relevant peptides have not been clarified, it has
been shown that direct conversion of the 55 amino acid
proapelin to apelin-13 by proprotein convertase subtilisin/
kexin 3 (PCSK3 or furin) [22] is possible, and short pep-
tides do not need to be cleaved from intermediate-length
peptides such as apelin-36. Following intravenous admin-
istration of [Pyr1]apelin-13 in rat the C-terminal phenyl-
alanine is cleaved or the peptide is hydrolysed between
Pro-10 and Met-11 [23]. Interestingly, apelin-13 and ape-
lin-36 are substrates of angiotensin-converting enzyme
(ACE)-2 that removes this C-terminal phenylalanine
[24]. This has been assumed to be an inactivating step
by generating biologically inert apelin metabolites; howev-
er, [Pyr1]apelin-13(1–12) retains comparable biological ac-
tivity to the full-length peptide and its endogenous
expression can be localised to endothelial cells [25]. Mo-
lecular modelling and biological evaluation of apelin
analogues in structure–activity studies reveal that the
RPRLS and KGPM sequences together with the RPRL b-
turn are necessary for receptor binding [16,26–28], with
specific residues within these two sequences being cru-
cial for determining agonist binding [16,29] and potency
[16,26,30]. Introduction of unnatural amino acids at the
C terminus of the apelin sequence can significantlyApelin-36
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Figure 1. Sequences of apelin and Elabela/Toddler peptides, apelin-36,
[Pyr1]apelin-13, Elabela/Toddler-32; Elabela/Toddler-21, Elabela/Toddler-11.
Three-letter codes of amino acid residues are shown. pGlu, pyroglutamate;
yellow lines represent disulfide bridges.enhance binding affinity, functional potency, and plasma
stability [31].
Synthetic agonists and biased agonists
Development of synthetic apelin agonists has included
cyclisation [32], PEGylation [33], and the synthesis of
lipopeptides based on 12-mer sections of the apelin recep-
tor [34]. Although useful as tool compounds, a limitation in
translation to clinic is that chronic administration of an
agonist will likely cause receptor desensitisation, with
subsequent b-arrestin-mediated downregulation and loss
of therapeutic efficacy. Therefore, the report of agonists
that are biased toward G protein signalling is encouraging.
E339-3D6 was described as a peptidomimetic agonist of
high molecular weight [35] but has subsequently been
shown to be a mixture of polymethylated species, the most
abundant of which has been purified and used to develop
several modified compounds including G protein biased
and non-biased analogues [36]. Removal of the C-terminal
phenylalanine of apelin-17 (apelin-17(1–16)) or [Pyr
1]apelin-
13 is reported to favour G protein over b-arrestin signalling
[25,37]. MM07 is a cyclic apelin peptide that preferentially
activates G protein responses with low potency in b-
arrestin and receptor internalisation assays. However, of
particular significance is that this peptide was an effective
dilator in human forearm, with no loss of effect on repeat
dosing, and MM07 increased cardiac output in the rat via a
load-independent effect, providing proof-of-concept of clin-
ical potential for biased agonists [38]. Intriguingly, where-
as the G protein biased MM07, a cyclic 13 amino acid
peptide, elicited vasodilatation in human forearm and
noradrenaline-constricted hand vein [38], apelin-17(1–16),
a linear unmodified peptide, also reported to be G protein
biased, lacked vasodilator capacity in an in vivo rat renal
afferent arteriolar preparation preconstricted with angio-
tensin II [37]. This may reflect differences in the peptide
used and/or the species and vascular bed investigated, or
may indicate a particular role for apelin receptor-mediated
b-arrestin signalling in the reversal of angiotensin II con-
striction. Small-molecule agonists are also in development,
and the first non-peptide agonist ML233 [39] was reported
to weakly inhibit forskolin-stimulated cAMP production
and exhibited full agonist activity in b-arrestin recruit-
ment in cells expressing the apelin receptor.
Apelin receptor antagonists
MM54, designed using a bivalent ligand approach, was the
first competitive apelin receptor antagonist reported with
nanomolar affinity for cloned human apelin receptor but
with no affinity for the AT1 receptor [40]. ML221 is a small-
molecule antagonist discovered from a high-throughput
screening programme with micromolar potency; however,
its utility is limited by its poor solubility and rapid metab-
olism [41]. A small-molecule antagonist that blocks the
CXC motif chemokine receptor CXCR4, ALX40-4C, also
blocks the apelin receptor as a coreceptor for HIV [42].
Physiological functions of apelin receptor signalling
A diverse range of physiological functions of apelin signal-
ling have emerged since its discovery. This review focuses
on the regulation of the cardiovascular system by apelin561
Review Trends in Pharmacological Sciences September 2015, Vol. 36, No. 9and its receptor. For reviews of other important functions
of apelin peptides including fluid homeostasis and metab-
olism see [4,43–45], and for the role of the apelin receptor
as a coreceptor for HIV infection see [46].
Apelin and apelin receptor knockout mice
Important insights into the cardiovascular roles of apelin
receptor signalling have been obtained from the generation
of apelin [47–49] and apelin receptor [49–51] knockout
mice. Apelin knockout mice have normal heart morphology
and blood pressure [47,49] but show a modest reduction in
basal cardiac contractile function [49]. These animals de-
velop impaired cardiac contractility with age [47] and have
a marked decrease in exercise capacity [49]. They develop
severe heart failure (HF) under pressure overload, that can
be rescued by inhibition of the AT1 receptor or infusion of
angiotensin 1–7 [47,52], and exhibit worsened pulmonary
hypertension under hypoxia [53]. In apelin knockouts,
following acute myocardial infarction infarct size and mor-
tality were increased [54], and with carotid ligation neoin-
timal lesion area was reduced [55].
Homozygous apelin receptor knockout mice are born in
sub-Mendelian ratio [49–51] owing to cardiovascular de-
velopmental defects, including poorly looped hearts with
aberrantly formed right ventricles, defective atrioventric-
ular cushion formation, and deformed vasculature of the
yolk sac and the embryo [8]. The surviving adult mice show
normal systolic blood pressure [50] and modest reduction
in basal cardiac contractile function [49]. There was a
striking decrease in exercise capacity [49], and these ani-
mals are more sensitive to angiotensin II following ACE
inhibition [50]. Interestingly, apelin receptor knockout
mice showed reduced cardiac hypertrophy and HF in re-
sponse to pressure overload [9]; however, this is an apelin
peptide-independent effect (see sections below on physio-
logical function and HF). Evidence that apelin receptor
activation opposes the angiotensin system is supported by
the apelin receptor/AT1 receptor double-knockout mouse
that exhibits elevated baseline blood pressure [50]. Overall,
information from deletion of peptide or receptor would
indicate that the apelin system is important for normal
cardiovascular development and function but is crucial for
appropriate protective responses under conditions of car-
diovascular stress. However, it is clear there are unex-
plained discrepancies in the phenotypes of the peptide and
receptor knockouts (Table 1).
Discovery of Elabela/Toddler
A possible explanation for these phenotypic discrepancies,
particularly in cardiovascular development, may comeTable 1. Comparison of apelin receptor-related phenotypes
Apln knockout mice Aplnr knockout mic
Mendelian birth ratio Loss of homozygou
Normal heart morphology Severe cardiac dev
Normal blood pressure Normal blood pres
Modest decrease in basal cardiac contractility Modest decrease in
Marked decrease in exercise capacity Marked decrease in
Severe heart failure in response to pressure
overload
Markedly reduced h
overload
562from the recently discovered Elabela/Toddler, whose gene,
apela, was identified in a conserved but previously desig-
nated non-coding region of the genome [56–58]. Apela
mutant zebrafish exhibit severe developmental defects
including rudimentary or absent heart formation, reminis-
cent of the apelin receptor phenotypes. In addition, the
Elabela/Toddler and apelin receptor spatiotemporal ex-
pression pattern, mutant rescue, and receptor internalisa-
tion experiments also suggest that Elabela/Toddler may be
a ligand of the apelin receptor. These studies predicted the
existence of three mature Elabela/Toddler peptides with
32, 21, and 11 amino acids (Figure 1) based on peptidase
cleavage [56,57].
A role for Elabela/Toddler beyond development can be
inferred from expression in adult human heart and blood
vessels, where Elabela/Toddler is localised to the endothe-
lium and nanomolar affinity of Elabela/Toddler was dem-
onstrated for the human apelin receptor [59]. In addition,
mRNA for Elabela/Toddler is expressed in human stem
cells, prostate, and kidney [56,60]. Elabela/Toddler acti-
vated signal transduction pathways downstream of over-
expressed human apelin receptor, promoted angiogenesis,
and induced vasodilatation in mouse aorta [60]. More
importantly, Elabela/Toddler attenuated the angiotensin
II-induced pressor effect in mouse in vivo [59].
Apelin receptor signalling in the cardiovascular system
In vivo, infusion of apelin into human forearm elicited
vasodilatation [38,61] with some evidence for contribution
from nitric oxide (NO) release [61]. Systemic apelin re-
duced blood pressure in anaesthetised and conscious rats
[38,62–64], in wild type but not apelin receptor-deficient
mice [50], and reduced mean arterial pressure and periph-
eral vascular resistance in humans [65]. In human isolated
blood vessels apelin has also been shown to produce both
NO-dependent [66] and NO-independent prostanoid-de-
pendent responses [20], and stimulated NO synthase
(NOS) activity and expression in rat aorta [67]
(Figure 2A). Removal of the endothelium results in vascu-
lar contraction in vitro [3,20]. These opposing endothelium-
dependent and -independent effects may reflect the activa-
tion of apelin receptors on endothelial versus smooth mus-
cle cells. Vasoconstriction may involve phosphorylation of
myosin light chain (MLC) via protein kinase C (PKC), Na+/
H+ exchanger (NHE), and Na+/Ca2+ exchanger (NCX),
together with inhibition of MLC phosphatase [68] or inhi-
bition of large-conductance Ca2+-activated K+ channels via
phosphatidylinositol 3-kinase (PI3K) [69] (Figure 2B).
Whether apelin-mediated vasoconstriction is physiologi-
cally relevant is debatable, but it may be of relevance ine Apela mutant zebrafish
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Figure 2. Proposed mechanisms of vasodilator and vasoconstrictor effects of
apelin. (A) Apelin activates endothelial apelin receptors producing vasodilatation
by pathways including release of NO. (B) In the absence of endothelium, apelin
activates apelin receptors on the underlying smooth muscle to cause
vasoconstriction. The apelin receptor is represented by the cell surface seven-
transmembrane receptor in red; broken arrows indicate unspecified intermediate
steps; + and  signs indicate positive and negative regulation,
respectively. Abbreviations: BKCa, large-conductance Ca
2+-activated K+ channel;
eNOS, endothelial nitric oxide synthase; MLC, myosin light chain; MLCP,
phosphorylated myosin light chain; NCX, Na+/Ca2+ exchanger; NHE, Na+/H+
exchanger; NO, nitric oxide; PGI2, prostacyclin; PI3K, phosphatidylinositol 3-
kinase; PKC, protein kinase C; sGC, soluble guanylyl cyclase; VEC, vascular
endothelial cells; VSMC, vascular smooth cells.
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Figure 3. Proposed mechanisms of apelin-induced positive inotropy and apelin-
independent stretch-induced hypertrophy. (A) Apelin activates apelin receptors on
cardiomyocytes to induce positive inotropy. (B) The apelin receptor mediates b-
arrestin-dependent signalling (orange) to cause hypertrophy in response to
stretch, whereas apelin-activated Gai signalling (black) is protective. The apelin
receptor is represented by the cell surface seven-transmembrane receptor in red;
broken arrows indicate unspecified intermediate steps; broken arrow with? mark
indicates unknown intermediate steps; + and  signs indicate positive and
negative regulation, respectively. Abbreviations: b-arr, b-arrestin; ERK1/2,
extracellular signal-regulated kinase 1/2; IP3, inositol trisphosphate; MEK1/2,
mitogen-activated protein kinase kinases 1/2; MLC, myosin light chain; MLCK,
myosin light chain kinase; NCX, Na+/Ca2+ exchanger; NHE1, Na+/H+ exchanger 1;
PKCe, protein kinase Ce; PLC, phospholipase C; SR, sarcoplasmic reticulum.
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peripheral actions, apelin may also modulate blood pres-
sure when administrated centrally, particularly when
injected into the subfornical organ, which detects circulat-
ing signals [70]. Furthermore, apelin and its receptor may
interact with other regulators of vascular tone. For exam-
ple, apelin counteracts the vasoconstrictor action of angio-
tensin II by a NO-dependent mechanism [71], as supported
by the apelin receptor knockout mouse [50].
In addition to an effect on the vasculature, apelin may
be an important regulator of cardiac contractility via acti-
vation of the receptor present on cardiomyocytes [18]. A
positive inotropic action of apelin has been demonstrated
in vivo in rats [72–74], mice [75], and humans [65] and is
supported by the decreased basal contractility observed in
apelin and apelin receptor knockout mice [49]. In addition,
chronic apelin infusion resulted in increased cardiac out-
put without hypertrophy in mice [75]. In human [20] and
rat [76] cardiac tissue apelin is reported to be a more-
potent positive inotrope than for example endothelin-1,
adrenomedullin, or urotensin-II.
In the heart, apelin signals via phospholipase C, PKCe,
NHE, NCX [76], and extracellular signal-regulated kinase
1/2 (ERK1/2), leading to activation of MLC kinase, in-
creased myofilament Ca2+ sensitivity [77], and increased
sarcomere shortening [78]. In addition, apelin may induce
positive inotropy by increasing [Ca2+]i transients and Ca
2+
availability independently of PKC [79,80] (Figure 3A).
The apelin receptor and cardiovascular development
The apelin receptor appears to be essential for normal
cardiac development, as shown by the severe cardiovascularphenotype of the receptor knockout mice [8]. A mutation
that causes a tryptophan to leucine substitution in the
second transmembrane domain of zebrafish apelin receptor
results in a deficit in cardiomyocyte number and may mani-
fest in pericardial oedema and absence of a heart [81]. It is
now known that Elabela/Toddler is the crucial developmen-
tal regulator in zebrafish; a murine apela knockout is an-
ticipated and will confirm whether this is also the case for
mammals. However, appropriate expression of apelin may
also be required for cardiac progenitor cells [81–83]. More-
over, normal vascular development also requires apelin
functioning as an angiogenic factor [84,85].
Targeting the apelin receptor in disease
Much of the current interest in apelin and the cardiovas-
cular system has focussed on the potential therapeutic
benefit of targeting the apelin receptor in pulmonary arte-
rial hypertension (PAH) and HF. By contrast, there is
currently less evidence supporting the contribution of
the apelin pathway in other cardiovascular conditions
(but see reviews [4,86]).
Pulmonary arterial hypertension
PAH is a fatal disease characterised by complex remodel-
ling of the pulmonary vasculature, that results in in-
creased pulmonary arterial pressure and vascular
resistance, leading to right ventricular hypertrophy and
eventually death from right ventricular failure [87]. Circu-
lating levels of apelin [53,88] and apelin expression in
pulmonary arterial endothelial cells (PAECs) [89] and
pulmonary microvascular endothelial cells (PMVECs)563
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deficiency exacerbates pulmonary hypertension in re-
sponse to hypoxia in mice [53]. Patients with PAH show
decreased expression and function of bone morphogenic
protein receptor type II (BMPR-II) with or without associ-
ated BMPR-II mutations [87]. Loss of BMPR-II function is
associated with upregulation of the miRNA miR-130/301
family [91] and reduction in the transcriptional activity of
PPARg, whose targets include apelin [90] (Figure 4). Im-
portantly, despite the reduction of apelin expression in
PAH, the receptor is present and can be targeted thera-
peutically [89,92]. The potential benefit of apelin agonists
is demonstrated by the ability of exogenous [Pyr1]apelin-13
to prevent the development of monocrotaline-induced PAH
[93]. Furthermore, apelin reverses established mild PAH
pathologies in mice with endothelial PPARg deletion
[90]. In addition, several studies using agents that indi-
rectly augment the apelin signalling pathway are benefi-
cial in PAH. For example, inhibiting the miR-130/301
family resulted in the reversal of established PAH [91],
as did administration of tacrolimus (FK506) or the endog-
enous elastase inhibitor elafin, which reportedly increased
apelin expression through enhancing BMPR-II signalling
[94,95]. Administration of miR424 and miR503, which are
anti-proliferative miRNAs regulated by apelin (Figure 4),
can also prevent and rescue PAH [89].
Apelin may be beneficial in PAH by influencing multiple
aspects of the disease. First, enhancing apelin signalling
lowered indices of pulmonary arterial pressure in animal
models [90,91,93]. This may be a consequence of apelin-
induced enhancement of pulmonary NOS expression [53]BMPR-II↓
Apelin↓
Apelin↓
PPARγ↓
KLF2↓ FGF2+FGFR1↑
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Figure 4. Summary of reported causes and consequences of reduced vascular
apelin levels in pulmonary arterial hypertension (PAH) lung. In PAH, reduced
BMPR-II expression and function, together with other stimuli, cause a reduction in
endothelial PPARg and, as a consequence, a reduction in the expression of the
PPARg transcriptional target apelin. Loss of apelin results in disinhibition of FGF2-
stimulated endothelial proliferation and smooth muscle cell proliferation, with a
potential reduction in apelin-mediated vascular dilatation. miRNA families may act
as important pathway components. Increase and decrease of the pathway
components in PAH are denoted by upward and downward arrows. The apelin
receptor is represented by the cell surface seven-transmembrane receptor in
red. Abbreviations: BMPR-II, bone morphogenic protein receptor type II; eNOS,
endothelial nitric oxide synthase; FGF2, fibroblast growth factor 2; KLF2, kruppel-
like factor 2; NO, nitric oxide; PAH-PAEC, pulmonary arterial endothelial cells in
pulmonary arterial hypertension; PASMC, pulmonary arterial smooth muscle cells;
PPARg, peroxisome proliferator-activated receptor g.
564and/or an attenuation of expression of vasoconstrictors
such as endothelin-1 and angiotensin II [93]. These effects
may rectify the imbalance between vasoconstrictors and
vasodilators in PAH.
Second, apelin may resolve the imbalance between pro-
liferation and apoptosis in PAH, thus limiting the extent of
vascular remodelling. Apelin promotes proliferation in
normal PAECs [89,90]; however, proliferation is attenuat-
ed in PAECs from PAH [89], and this may be a consequence
of normalised expression of miR-424 and miR-503 and
their targets fibroblast growth factor 2 and its receptor
[89] (Figure 4). However, apelin promotes survival in both
normal and PAH PMVECs [90], suggesting that further
investigation will be necessary to clarify whether the role of
apelin is to restore normal endothelial function and/or to
suppress unregulated endothelial cell proliferation in
PAH. A recent study reported that apelin potentiated
the ATPase activity of the endothelial enzyme CD39 in
vitro and in vivo, whereas suppression of CD39 gave rise to
apoptosis-resistant PAECs which may be responsible for
advanced vascular lesions in PAH [96]. By contrast, the
effect of apelin on pulmonary arterial smooth muscle cells
is consistently anti-proliferative and pro-apoptotic [89,90]
and anti-migratory [96], indicating that loss of apelin in
PAH results in reduced suppression of smooth muscle cell
proliferation that is a hallmark of the disease. Overall,
apelin protects against arterial muscularisation and the
loss of microvessels in vivo [53,89–91].
Finally, in addition to effects on the pulmonary vascu-
lature, apelin may also beneficially augment right ventric-
ular performance in PAH. Apelin increased contractility in
trabeculae from failing right ventricle caused by hypoxia-
induced pulmonary hypertension [79], and did not induce
cardiac or cardiomyocyte hypertrophy [75]. More impor-
tantly, in vivo studies using PAH models consistently
reported reduced right ventricular hypertrophy in re-
sponse to administered apelin [90,93].
Left ventricular HF
In addition to right ventricular failure in PAH, enhancing
apelin receptor signalling may also be beneficial in left
ventricular HF. In humans, plasma apelin levels are unal-
tered or increased in early stages of HF [97,98], but re-
duced in advanced disease [97,99–101]. These results
suggest an initial compensatory increase in apelin to
improve cardiac contractility but, as the disease pro-
gresses, apelin is reduced or lost. Interestingly, apelin
peptide levels are elevated in plasma after cardiac resyn-
chronisation therapy [101] and in cardiac tissue following
ventricular offloading [97]. In animal models of HF, the
initial preservation and later downregulation of apelin in
severe disease are also observed, recapitulating the human
condition [73,102–104]. More importantly, apelin knockout
mice develop progressive left ventricular dysfunction with
age and severe HF with pressure overload [47].
The effect of HF on apelin receptor expression is less
clear, and levels were reportedly unchanged or reduced in
patients with cardiomyopathies [99], and unaltered, re-
duced, or increased in animal models of HF [73,74,102–
104]. Of interest, the apelin receptor was the most upre-
gulated of 12 000 genes following ventricular offloading
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reported; however, only the 212A allele of a 50 untranslated
region polymorphism has been associated with slowing of
HF progression [105]. Furthermore, an apelin-indepen-
dent stretch-sensitive function of the receptor may mediate
myocardial hypertrophy and HF in response to chronic
pressure overload via b-arrestin signalling, whereas ape-
lin-induced Gai signalling is protective [9], indicating a
potential advantage of Gai-biased agonists in this condition
[38] (Figure 3B).
Therefore, as predicted, exogenous apelin is beneficial in
a range of animal HF models [72–74,103,104,106], and
retained or enhanced the inotropic action of apelin
[72,78,79] and attenuated left ventricular hypertrophy
[107]. Similarly, in HF patients, infusion of apelin locally
caused vasodilatation [65,108] despite evidence of endo-
thelial dysfunction indicated by attenuated dilatation in-
duced by acetylcholine [108]. Systemically, apelin
increased cardiac index, reduced peripheral vascular re-
sistance, and moderately lowered mean arterial pressure,
without an increase in heart rate [65]. These actions of
apelin were preserved during prolonged infusion and un-
der conditions of renin/angiotensin system activation
[108].
Emerging evidence suggests that apelin receptor signal-
ling is beneficial beyond established HF and confers car-
dioprotection during myocardial injury. Cardiac apelin
expression was upregulated in response to hypoxia/ischae-
mia [109,110]. Apelin deficiency worsened outcome in
myocardial infarction and ischaemia–reperfusion injury
[54]. By contrast, apelin administration during reperfusion
or post-infarct reduced infarct size and ameliorated heart
dysfunction via cardioprotective mechanisms, including
activation of the reperfusion injury salvage kinase path-
way, which may involve PI3K-protein kinase B or ERK,
reduction of apoptosis and reactive oxygen species produc-
tion, and increased NO production [111–114].
Concluding remarks
The discovery of a second peptide, Elabela/Toddler, pro-
vides an elegant explanation of why apelin peptide knock-
out does not recapitulate the dramatic failure of the
cardiovascular system to develop following deletion of
the apelin receptor gene. The identification of apela within
a region of the genome hitherto classified as ‘non-coding’
may hold the key to the identification of endogenous li-
gands for the remaining 130 orphan GPCRs [115]. It is
remarkable that two peptides with so little sequence simi-
larity can activate a single receptor, and the challenge will
be to understand how these act spatiotemporally. Compel-
ling evidence suggests that the apelin receptor is one of the
first GPCR pathways tractable to the design of biased
agonists with proof-of-concept for utility in the clinic.
Further studies will reveal whether such biased agonists
will revolutionise our understanding of pharmacology and
drug discovery in the future.
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